NASDAQ:PTN - Palatin Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.8019 +0.01 (+1.26 %) (As of 02/21/2019 06:24 AM ET)Previous Close$0.7924Today's Range$0.79 - $0.8352-Week Range$0.59 - $1.59Volume866,883 shsAverage Volume650,141 shsMarket Capitalization$162.84 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation. In addition, the company develops natriuretic peptide system programs, including PL3994, a natriuretic peptide receptor-A agonist for treatment of cardiovascular indications; and PL-5028, s dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey. Receive PTN News and Ratings via Email Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic Substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTN Previous Symbol CUSIPN/A Webwww.palatin.com PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares203,063,000Market Cap$162.84 million OptionableNot Optionable Palatin Technologies (NASDAQ:PTN) Frequently Asked Questions What is Palatin Technologies' stock symbol? Palatin Technologies trades on the NASDAQ under the ticker symbol "PTN." When is Palatin Technologies' next earnings date? Palatin Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Palatin Technologies. What is the consensus analysts' recommendation for Palatin Technologies? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies. Has Palatin Technologies been receiving favorable news coverage? Press coverage about PTN stock has been trending somewhat positive recently, according to InfoTrie. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Palatin Technologies earned a news impact score of 0.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Palatin Technologies' key competitors? Some companies that are related to Palatin Technologies include Quotient (QTNT), Intellia Therapeutics (NTLA), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), Vermillion (VRML), Riot Blockchain (RIOT), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Akers Biosciences (AKER), GeneNews (GNWSF), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI) and BG Medicine (BGMD). Who are Palatin Technologies' key executives? Palatin Technologies' management team includes the folowing people: Dr. John K. A. Prendergast Ph.D., Co-Founder & Non-Exec. Chairman (Age 64)Dr. Carl Spana Ph.D., Co-Founder, Pres, CEO & Director (Age 56)Mr. Stephen T. Wills CPA, MST, CFO, COO, Principal Accounting Officer, executive VP, Treasurer & Sec. (Age 61)Burns McClellan, VP of Investor RelationsDr. Johna Lucas M.A., M.D., F.A.C.O.G., Chief Medical Officer How do I buy shares of Palatin Technologies? Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Palatin Technologies' stock price today? One share of PTN stock can currently be purchased for approximately $0.8019. How big of a company is Palatin Technologies? Palatin Technologies has a market capitalization of $162.84 million. What is Palatin Technologies' official website? The official website for Palatin Technologies is http://www.palatin.com. MarketBeat Community Rating for Palatin Technologies (NASDAQ PTN)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 36 (Vote Outperform)Underperform Votes: 23 (Vote Underperform)Total Votes: 59MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: What is a Futures Contract?